Romiplostim (Nplate^®) as an effective radiation countermeasure to improve survival and platelet recovery in mice

References

• Booth C, Tudor G, Tudor J, Katz BP, MacVittie TJ. 2012. Acute gastrointestinal syndrome in high-dose irradiated mice. Health Phys. 103:383–399.
   PubMed Web of Science ®Google Scholar
• Broudy VC, Lin NL. 2004. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 25:52–60.
   PubMed Web of Science ®Google Scholar
• Chua HL, Plett PA, Sampson CH, Katz BP, Carnathan GW, MacVittie TJ, Lenden K, Orschell CM. 2014. Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 106:21–38.
   PubMed Web of Science ®Google Scholar
• Daw NC, Arnold JT, Abushullaih BA, Stenberg PE, White MM, Jayawardene D, Srivastava DK, Jackson CW. 1998. A single intravenous dose of murine megakaryocyte growth and development factor potently stimulates platelet production, challenging the necessity for daily administration. Blood. 91:466–474.
   PubMed Web of Science ®Google Scholar
• Farese AM, Cohen MV, Stead RB, Jackson W, 3rd, Macvittie TJ. 2012. Pegfilgrastim administered in an abbreviated schedule, significantly improved neutrophil recovery after high-dose radiation-induced myelosuppression in rhesus macaques. Radiat Res. 178:403–413.
   PubMed Web of Science ®Google Scholar
• Gellens R, Habchi S, Freppel S, Couret D, Iacobelli S. 2017. Romiplostim for the emergency management of severe immune thrombocytopenia with intracerebral hemorrhage. Front Neurol. 8:737.
   PubMed Web of Science ®Google Scholar
• Handtke S, Steil L, Greinacher A, Thiele T. 2018. Toward the relevance of platelet subpopulations for transfusion medicine. Front Med (Lausanne). 5:17.
   PubMed Web of Science ®Google Scholar
• Hankey KG, Farese AM, Blaauw EC, Gibbs AM, Smith CP, Katz BP, Tong Y, Prado KL, MacVittie TJ. 2015. Pegfilgrastim improves survival of lethally irradiated nonhuman primates. Radiat Res. 183:643–655.
   PubMed Web of Science ®Google Scholar
• Hirouchi T, Ito K, Nakano M, Monzen S, Yoshino H, Chiba M, Hazawa M, Nakano A, Ishikawa J, Yamaguchi M, et al. 2015. Mitigative effects of a combination of multiple pharmaceutical drugs on the survival of mice exposed to lethal ionizing radiation. Curr Pharm Biotechnol. 17:190–199.
   PubMed Web of Science ®Google Scholar
• Krzyzanski W, Sutjandra L, Perez-Ruixo JJ, Sloey B, Chow AT, Wang YM. 2013. Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals. Pharm Res. 30:655–669.
   PubMed Web of Science ®Google Scholar
• LEUKINE® (sargramostim) [product monograph]: Bridgewater, NJ: Sanofi-Aventis US Inc.
   Google Scholar
• Levin J, Levin FC, Hull DF, 3rd, Penington DG. 1982. The effects of thrombopoietin on megakaryocyte-cfc, megakaryocytes, and thrombopoiesis: with studies of ploidy and platelet size. Blood. 60:989–998.
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 98:3241–3248.
   PubMed Web of Science ®Google Scholar
• Molineux G, Newland A. 2010. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol. 150:9–20.
   PubMed Web of Science ®Google Scholar
• National Library of Medicine, National Institues of Health, U.S. Department of Health and Human Services, Radiation Emergency Medical Management. 2018. Myeloid Cytokines for Acute Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Subsyndrome of ARS). ; [updated June 30, 2018; accessed January 18, 2019]. https://www.remm.nlm.gov/cytokines.htm.
   Google Scholar
• NEULASTA® (pegfilgrastim) [product monograph]: Thousand Oaks, CA: Amgen Inc.
   Google Scholar
• NEUPOGEN® (filgrastim) [product monograph]: Thousand Oaks, CA: Amgen Inc.
   Google Scholar
• NPLATE® (romiplostim) [product monograph]: Thousand Oaks, CA: Amgen Inc.
   Google Scholar
• Plett PA, Sampson CH, Chua HL, Jackson W, Vemula S, Sellamuthu R, Fisher A, Feng H, Wu T, MacVittie TJ, et al. 2015. The H-ARS dose response relationship (DRR): validation and variables. Health Phys. 109:391–398.
   PubMed Web of Science ®Google Scholar
• Plett PA, Sampson CH, Chua HL, Joshi M, Booth C, Gough A, Johnson CS, Katz BP, Farese AM, Parker J, et al. 2012. Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys. 103:343–355.
   PubMed Web of Science ®Google Scholar
• Provan D, Newland A. 2007. Romiplostim. Drugs Fut. 32:781–787.
   Web of Science ®Google Scholar
• Singh VK, Newman VL, Seed TM. 2015. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review. Cytokine. 71:22–37.
   PubMed Web of Science ®Google Scholar
• Singh VK, Seed TM. 2017. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures. Int J Radiat Biol. 93:851–869.
   PubMed Web of Science ®Google Scholar
• Stickney DR, Dowding C, Authier S, Garsd A, Onizuka-Handa N, Reading C, Frincke JM. 2007. 5-androstenediol improves survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression. Int Immunopharmacol. 7:500–505.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services Press Office. 2016. HHS enhances nation's health preparedness for radiological threats. ; [updated October 6, 2016; accessed January 18, 2019]. https://wayback.archive-it.org/3926/20170128052606/https://www.hhs.gov/about/news/2016/10/06/hhs-enhances-nation-s-health-preparedness-radiological-threats.html.
   Google Scholar
• Wang B, Nichol JL, Sullivan JT. 2004. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 76:628–638.
   PubMed Web of Science ®Google Scholar
• Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Perez-Ruixo JJ, Chow AT. 2010. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 12:729–740.
   PubMed Web of Science ®Google Scholar
• Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley AL, Dickerson WE, Tsu H, Confer DL, Coleman CN, Seed T, et al. 2004. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med. 140:1037–1051.
   PubMed Web of Science ®Google Scholar
• Williams JP, Brown SL, Georges GE, Hauer-Jensen M, Hill RP, Huser AK, Kirsch DG, Macvittie TJ, Mason KA, Medhora MM, et al. 2010. Animal models for medical countermeasures to radiation exposure. Radiat Res. 173:557–578.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Hirouchi T, Yokoyama K, Nishiyama A, Murakami S, Kashiwakura I. 2018. The thrombopoietin mimetic romiplostim leads to the complete rescue of mice exposed to lethal ionizing radiation. Sci Rep. 8:10659.
   PubMed Web of Science ®Google Scholar